{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:48:49Z","timestamp":1791582529601,"version":"4.3.4"},"reference-count":226,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T00:00:00Z","timestamp":1558396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001253","name":"Multiple Myeloma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001253","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.01121","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T04:55:54Z","timestamp":1558414554000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":146,"title":["Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma"],"prefix":"10.3389","volume":"10","author":[{"given":"Benjamin G.","family":"Barwick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas A.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula M.","family":"Vertino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence H.","family":"Boise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1177\/095952874402700129","article-title":"Remarks on the pathology of mollities ossium; with cases","volume":"27","author":"Solly","year":"1844","journal-title":"Med Chir Trans."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma ASH 50th anniversary review Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0140-6736(02)86528-X","article-title":"Chemical pathology","volume":"2","author":"Jones","year":"1847","journal-title":"Lancet"},{"key":"B4","first-page":"55","article-title":"On a New Substance Occurring in the Urine of a Patient with Mollities Ossium","volume-title":"Philosophical Transactions of the Royal Society of London.","author":"Jones","year":"1848"},{"key":"B5","unstructured":"An inquiry into the causes and effects of the variolae vaccinae, or cow-pox JennerEI EdwardJ The Three Original Publications on Vaccination Against Smallpox1798"},{"key":"B6","first-page":"1113","article-title":"The mechanism of immunity in animals to diphtheria and tetanus","volume":"16","author":"van Behring","year":"1890","journal-title":"Deutsche Medizinsche Wochenschrift"},{"key":"B7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1365-3083.1990.tb02737.x","article-title":"Paul ehrlich - nobel lecture: partial cell functions","volume":"31","author":"Ehrlich","year":"1990","journal-title":"Scand J Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/BF02933794","article-title":"Ueber Bindegewebszellen","volume":"11","author":"Waldeyer","year":"1875","journal-title":"Arch f\u00fcr Mikroskopische Anat"},{"key":"B9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/BF02911073","article-title":"Multiples myelom","volume":"3","author":"Rustizky","year":"1873","journal-title":"Dtsch Zeitschrift f\u00fcr Chir"},{"key":"B10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/bjs.1800249517","article-title":"A case of multiple myeloma","volume":"15","author":"Wright","year":"1900","journal-title":"Br Soc Med Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/159499a0","article-title":"Plasma cellular reaction and its relation to the formation of antibodies in vitro","volume":"159","author":"Fagraeus","year":"1947","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/1097-0142(195603\/04)9:2<262::AID-CNCR2820090210>3.0.CO;2-B","article-title":"Multiple-myeloma proteins","volume":"9","author":"Korngold","year":"1956","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1084\/JEM.116.2.207","article-title":"The nature of Bence-Jones proteins","volume":"116","author":"Edelman","year":"1962","journal-title":"J Exp Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/205143a0","article-title":"Delineation of the thymic and bursal lymphoid systems in the chicken","volume":"205","author":"Cooper","year":"1965","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nri3801","article-title":"The early history of B cells","volume":"15","author":"Cooper","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B16","first-page":"211","article-title":"Studies on conditions associated with disturbed gamma globulin formation (gammopathies)","volume":"56","author":"Waldenstrom","year":"","journal-title":"Harvey Lect"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"B18","unstructured":""},{"key":"B19","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"key":"B22","first-page":"578","article-title":"Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)","volume":"25","author":"Kyle","year":"2011","journal-title":"Oncology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1182\/blood-2014-05-578732","article-title":"The Tao of myeloma","volume":"124","author":"Boise","year":"2014","journal-title":"Blood."},{"key":"B24","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1146\/annurev.immunol.19.1.595","article-title":"B cell development pathways","volume":"19","author":"Hardy","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.immuni.2007.05.010","article-title":"The transcriptional regulation of B cell lineage commitment","volume":"26","author":"Nutt","year":"2007","journal-title":"Immunity."},{"key":"B26","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nri1572","article-title":"Regulation of plasma-cell development","volume":"5","author":"Shapiro-Shelef","year":"2005","journal-title":"Nat Rev Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1600-065X.2010.00940.x","article-title":"Plasma cell development and survival","volume":"237","author":"Oracki","year":"2010","journal-title":"Immunol Rev"},{"key":"B28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.smim.2007.12.002","article-title":"Plasma cell development: from B-cell subsets to long-term survival niches","volume":"20","author":"Fairfax","year":"2008","journal-title":"Semin Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1101\/gad.320192.118","article-title":"Molecular regulation of peripheral B cells and their progeny in immunity","volume":"33","author":"Boothby","year":"2019","journal-title":"Genes Dev"},{"key":"B30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0008-8749(74)90232-9","article-title":"Differentiation of lymphocytes in mouse bone marrow","volume":"131","author":"Osmond","year":"1974","journal-title":"Cell Immunol"},{"key":"B31","doi-asserted-by":"crossref","first-page":"719","DOI":"10.4049\/jimmunol.113.3.719","article-title":"Mouse bone marrow lymphocytes and their differentiation","volume":"113","author":"Ryser","year":"1974","journal-title":"J Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/249361a0","article-title":"In vitro generation of B lymphocytes in mouse foetal liver, a mammalian \u2018bursa equivalent","volume":"249","author":"Owen","year":"1974","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/0092-8674(94)90077-9","article-title":"E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements","volume":"79","author":"Bain","year":"1994","journal-title":"Cell."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1126\/science.8079170","article-title":"Requirement of transcription factor PU","volume":"265","author":"Scott","year":"1994","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/44076","article-title":"Commitment to the B-lymphoid lineage depends on the transcription factor Pax5","volume":"401","author":"Nutt","year":"1999","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"crossref","first-page":"9125","DOI":"10.1073\/pnas.90.19.9125","article-title":"Expression and function of the interleukin 7 receptor in murine lymphocytes","volume":"90","author":"Sudo","year":"1993","journal-title":"Proc Natl Acad Sci USA."},{"key":"B37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood.V96.1.9","article-title":"Fate of B cell development","volume":"96","author":"Lebien","year":"2000","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2008-02-078071","article-title":"B lymphocytes: how they develop and function","volume":"112","author":"LeBien","year":"2008","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0092-8674(93)90167-O","article-title":"Interleukin-2 receptor \u03b3 chain mutation results in X-linked severe combined immunodeficiency in humans","volume":"73","author":"Noguchi","year":"1993","journal-title":"Cell."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/0092-8674(89)90760-5","article-title":"The V(D)J recombination activating gene, RAG-1","volume":"59","author":"Schatz","year":"1989","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1126\/science.2360047","article-title":"RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination","volume":"248","author":"Oettinger","year":"1990","journal-title":"Science."},{"key":"B42","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/280288a0","article-title":"Sequences at the somatic recombination sites of immunoglobulin light-chain genes","volume":"280","author":"Sakano","year":"1979","journal-title":"Nature."},{"key":"B43","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1182\/blood-2004-09-3740","article-title":"B-cell kinetics in humans: rapid turnover of peripheral blood memory cells","volume":"105","author":"Macallan","year":"2005","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.cell.2013.04.033","article-title":"Global regulation of promoter melting in naive lymphocytes","volume":"153","author":"Kouzine","year":"2013","journal-title":"Cell"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/ni.3519","article-title":"Plasma cell differentiation is coupled to division-dependent DNA hypomethylation and gene regulation","volume":"17","author":"Barwick","year":"2016","journal-title":"Nat Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/41131","article-title":"A human homologue of the Drosophila Toll protein signals activation of adaptive immunity","volume":"388","author":"Medzhitov","year":"1997","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"crossref","first-page":"940","DOI":"10.4049\/jimmunol.109.5.940","article-title":"H-2 Dependence of co-operation between T and B cells in vivo","volume":"109","author":"Kindred","year":"1972","journal-title":"J Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/357080a0","article-title":"Molecular and biological characterization of a murine ligand for CD40","volume":"357","author":"Armitage","year":"1992","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1073\/pnas.89.14.6550","article-title":"A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells","volume":"89","author":"Noelle","year":"1992","journal-title":"Proc Natl Acad Sci USA."},{"key":"B50","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.4049\/jimmunol.136.7.2348","article-title":"Two types of murine helper T cell clone","volume":"136","author":"Mosmann","year":"1986","journal-title":"J Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1126\/science.3107127","article-title":"Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production","volume":"236","author":"Snapper","year":"1987","journal-title":"Science."},{"key":"B52","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1084\/JEM.167.2.332","article-title":"The essential role of B cell stimulatory factor 2 (BSF-2\/IL-6) for the terminal differentiation of B cells","volume":"167","author":"Muraguchi","year":"1988","journal-title":"J Exp Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/332083a0","article-title":"Autocrine generation and requirement of BSF-2\/IL-6 for human multiple myelomas","volume":"332","author":"Kawano","year":"1988","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1146\/annurev.iy.12.040194.001001","article-title":"Germinal centers","volume":"12","author":"MacLennan","year":"1994","journal-title":"Annu Rev Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1146\/annurev-immunol-020711-075032","article-title":"Germinal centers","volume":"30","author":"Victora","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/354389a0","article-title":"Intraclonal generation of antibody mutants in germinal centres","volume":"354","author":"Jacob","year":"1991","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S0092-8674(00)00078-7","article-title":"Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme","volume":"102","author":"Muramatsu","year":"2000","journal-title":"Cell"},{"key":"B58","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0092-8674(90)90248-D","article-title":"Circular DNA is excised by immunoglobulin class switch recombination","volume":"62","author":"Iwasato","year":"1990","journal-title":"Cell."},{"key":"B59","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/0092-8674(90)90247-C","article-title":"Switch circular DNA formed in cytokine-treated mouse splenocytes: evidence for intramolecular DNA deletion in immunoglobulin class switching","volume":"62","author":"Matsuoka","year":"1990","journal-title":"Cell"},{"key":"B60","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/345452a0","article-title":"Circular DNA is a product of the immunoglobulin class switch rearrangement","volume":"345","author":"Von Schwedler","year":"1990","journal-title":"Nature"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1182\/blood-2003-02-0493","article-title":"The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma","volume":"102","author":"Fonseca","year":"2003","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","first-page":"5611","DOI":"10.1038\/sj.onc.1204641","article-title":"Chromosomal translocations in multiple myeloma","volume":"20","author":"Bergsagel","year":"2001","journal-title":"Oncogene."},{"key":"B63","doi-asserted-by":"publisher","first-page":"6333","DOI":"10.1200\/JCO.2005.05.021","article-title":"Molecular pathogenesis and a consequent classification of multiple myeloma","volume":"23","author":"Bergsagel","year":"2005","journal-title":"J Clin Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrc746","article-title":"Multiple myeloma: evolving genetic events and host interactions","volume":"2","author":"Kuehl","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"B65","doi-asserted-by":"publisher","first-page":"13931","DOI":"10.1073\/pnas.93.24.13931","article-title":"Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma","volume":"93","author":"Bergsagel","year":"1996","journal-title":"Proc Natl Acad Sci USA."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/s41467-019-09555-6","article-title":"Multiple myeloma immunoglobulin lambda translocations portend poor prognosis","volume":"10","author":"Barwick","year":"2019","journal-title":"Nat Commun."},{"key":"B67","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1182\/blood.V98.1.217","article-title":"Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma","volume":"98","author":"Shaughnessy","year":"2001","journal-title":"Blood"},{"key":"B68","first-page":"5640","article-title":"High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies","volume":"58","author":"Avet-Loiseau","year":"1998","journal-title":"Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","article-title":"Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma","volume":"106","author":"Bergsagel","year":"2005","journal-title":"Blood."},{"key":"B70","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1535-6108(04)00019-4","article-title":"Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma","volume":"5","author":"Hurt","year":"2004","journal-title":"Cancer Cell"},{"key":"B71","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1182\/blood-2012-12-471888","article-title":"Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells","volume":"121","author":"Walker","year":"2013","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1084\/JEM.150.4.792","article-title":"Studies on the clonal origin of multiple myeloma","volume":"150","author":"Kubagawa","year":"1979","journal-title":"J Exp Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","author":"P\u00e9rez-Gal\u00e1n","year":"2011","journal-title":"Blood."},{"key":"B74","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood.V92.9.3025","article-title":"The t(4;14) translocation in myeloma dysregulates both FGFR3and a novel gene, MMSET, resulting in IgH\/MMSET hybrid transcripts","volume":"92","author":"Chesi","year":"1998","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/ng0797-260","article-title":"Frequent translocation t(4;14)(p16","volume":"16","author":"Chesi","year":"1997","journal-title":"Nat Genet."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1182\/blood-2002-06-1675","article-title":"In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression","volume":"101","author":"Keats","year":"2003","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1182\/blood-2004-09-3704","article-title":"Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients","volume":"105","author":"Keats","year":"2005","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1182\/blood-2010-07-298349","article-title":"The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells","volume":"117","author":"Martinez-Garcia","year":"2011","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","first-page":"e1004566","DOI":"10.1371\/journal.pgen.1004566","article-title":"Histone methyltransferase MMSET\/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation","volume":"10","author":"Popovic","year":"2014","journal-title":"PLoS Genet"},{"key":"B80","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1182\/blood.V91.12.4457","article-title":"Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma","volume":"91","author":"Chesi","year":"1998","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/j.1349-7006.2001.tb01142.x","article-title":"Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations","volume":"92","author":"Hanamura","year":"2001","journal-title":"Japanese J Cancer Res"},{"key":"B82","first-page":"2140","article-title":"WWOX , a novel WW domain-containing protein mapping to affected in breast cancer advances in brief","volume":"60","author":"Bednarek","year":"2000","journal-title":"Cancer Res"},{"key":"B83","first-page":"8068","article-title":"WWOX, the FRA16D gene, behaves as a suppressor of tumor growth","volume":"61","author":"Bednarek","year":"2001","journal-title":"Cancer Res."},{"key":"B84","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1200\/JCO.2008.20.6136","article-title":"Prognostic significance of copy-number alterations in multiple myeloma","volume":"27","author":"Avet-Loiseau","year":"2009","journal-title":"J Clin Oncol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/ejh.12688","article-title":"Cytogenetics in multiple myeloma patients progressing into extramedullary disease","volume":"97","author":"Besse","year":"2016","journal-title":"Eur J Haematol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My\u00e9lome","volume":"109","author":"Attal","year":"2007","journal-title":"Blood"},{"key":"B87","first-page":"4546","article-title":"14Q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma","volume":"59","author":"Avet-Loiseau","year":"1999","journal-title":"Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/sj.leu.2404442","article-title":"Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials","volume":"21","author":"Anderson","year":"2006","journal-title":"Leukemia"},{"key":"B89","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"key":"B90","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ccr.2009.11.019","article-title":"The DLEU2\/miR-15a\/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia","volume":"17","author":"Ambesi-Impiombato","year":"2010","journal-title":"Cancer Cell"},{"key":"B92","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/gcc.10140","article-title":"Delineation of the minimal region of loss at 13q14 in multiple myeloma","volume":"36","author":"Elnenaei","year":"2003","journal-title":"Genes, Chromosom Cancer"},{"key":"B93","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1038\/sj.leu.2404403","article-title":"Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma","volume":"20","author":"Fonseca","year":"2006","journal-title":"Leukemia"},{"key":"B94","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1182\/blood-2010-04-279596","article-title":"A compendium of myeloma associated chromosomal copy number abnormalities and their prognostic value","volume":"116","author":"Walker","year":"2010","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"B96","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/10245330512331390140","article-title":"Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27 Kip1 and an aggressive clinical course in multiple myeloma","volume":"10","author":"Shaughnessy","year":"2005","journal-title":"Hematology"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/35060126","article-title":"The cell-cycle regulatory protein Cks1 is required for SCFSkp2-mediated ubiquitinylation of p27","volume":"3","author":"Tyers","year":"2002","journal-title":"Nat Cell Biol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J Clin Oncol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/ni.2527","article-title":"Mcl-1 is essential for the survival of plasma cells","volume":"14","author":"Peperzak","year":"2013","journal-title":"Nat Immunol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1073\/PNAS.90.8.3516","article-title":"MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2","volume":"90","author":"Kozopas","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1182\/blood.V99.6.1885","article-title":"Myeloid cell factor-1 is a critical survival factor for multiple myeloma","volume":"99","author":"Zhang","year":"2002","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat Commun"},{"key":"B104","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Discov"},{"key":"B106","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/blood.V98.7.2229","article-title":"Hypodiploidy is a major prognostic factor in multiple myeloma","volume":"98","author":"V\u00e9 Ronique Smadja","year":"2001","journal-title":"Blood."},{"key":"B107","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International myeloma working group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"key":"B108","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1093\/nar\/gkw222","article-title":"FAM46 proteins are novel eukaryotic non-canonical poly(A) polymerases","volume":"44","author":"Pawlowski","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"B109","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41467-017-00578-5","article-title":"The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in multiple myeloma","volume":"8","author":"Mroczek","year":"2017","journal-title":"Nat Commun"},{"key":"B110","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1158\/0008-5472.CAN-16-3011","article-title":"Loss of FAM46C promotes cell survival in myeloma","volume":"77","author":"Zhu","year":"2017","journal-title":"Cancer Res"},{"key":"B111","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1073\/pnas.97.1.228","article-title":"Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma","volume":"97","author":"Shou","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/leu.2014.70","article-title":"Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma","volume":"28","author":"Affer","year":"2014","journal-title":"Leukemia"},{"key":"B113","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","article-title":"AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies","volume":"13","author":"Chesi","year":"2008","journal-title":"Cancer Cell"},{"key":"B114","doi-asserted-by":"publisher","first-page":"7824","DOI":"10.1073\/pnas.79.24.7824","article-title":"Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells","volume":"79","author":"Dalla-Favera","year":"1982","journal-title":"Proc Natl Acad Sci USA."},{"key":"B115","doi-asserted-by":"publisher","first-page":"7837","DOI":"10.1073\/pnas.79.24.7837","article-title":"Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells","volume":"79","author":"Taub","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"key":"B116","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1038\/bcj.2014.13","article-title":"Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients","volume":"4","author":"Walker","year":"2014","journal-title":"Blood Cancer J"},{"key":"B117","doi-asserted-by":"publisher","first-page":"8189","DOI":"10.1093\/nar\/gkw527","article-title":"Frequent occurrence of large duplications at reciprocal genomic rearrangement breakpoints in multiple myeloma and other tumors","volume":"44","author":"Demchenko","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.cell.2014.11.014","article-title":"Convergent transcription at intragenic super-enhancers targets AID-initiated genomic instability","volume":"159","author":"Meng","year":"2014","journal-title":"Cell"},{"key":"B119","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/316260a0","article-title":"A uniform deleting element mediates the loss of \u03ba genes in human B cells","volume":"316","author":"Siminovitch","year":"1985","journal-title":"Nature"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2008.4","article-title":"Genetic aberrations and survival in plasma cell leukemia","volume":"22","author":"Tiedemann","year":"2008","journal-title":"Leukemia."},{"key":"B121","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3389\/fonc.2018.00665","article-title":"Deregulation and targeting of TP53 pathway in multiple myeloma","volume":"8","author":"Manier","year":"2019","journal-title":"Front Oncol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","article-title":"Promiscuous mutations activate the noncanonical NF-\u03baB pathway in multiple myeloma","volume":"12","author":"Keats","year":"2007","journal-title":"Cancer Cell."},{"key":"B123","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ccr.2007.07.004","article-title":"Frequent engagement of the classical and alternative NF-\u03baB pathways by diverse genetic abnormalities in multiple myeloma","volume":"12","author":"Annunziata","year":"2007","journal-title":"Cancer Cell"},{"key":"B124","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/0092-8674(86)90346-6","article-title":"Multiple nuclear factors interact with the immunoglobulin enhancer sequences","volume":"46","author":"Sen","year":"1986","journal-title":"Cell"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.4049\/jimmunol.168.3.1259","article-title":"Regulation of human ig light chain gene expression by NF- B","volume":"168","author":"Combriato","year":"2014","journal-title":"J Immunol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"B127","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P Somatic Mutation in Waldenstr\u00f6m's Macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med"},{"key":"B128","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"key":"B129","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1182\/blood.V88.7.2699.bloodjournal8872699","article-title":"Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial","volume":"88","author":"Liu","year":"1996","journal-title":"Blood"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1101\/563312","article-title":"Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma","author":"Lin","year":"2019","journal-title":"bioRxiv"},{"key":"B131","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1182\/blood.V97.3.729","article-title":"Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma","volume":"97","author":"Chesi","year":"2001","journal-title":"Blood"},{"key":"B132","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"B133","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1182\/blood-2009-12-261032","article-title":"Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients","volume":"116","author":"Broyl","year":"2010","journal-title":"Blood"},{"key":"B134","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","article-title":"Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma","volume":"24","author":"Ledergor","year":"2018","journal-title":"Nat Med"},{"key":"B135","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/ni.3154","article-title":"Transcriptional profiling of mouse B cell terminal differentiation defines a signature for antibody-secreting plasma cells","volume":"16","author":"Shi","year":"2015","journal-title":"Nat Immunol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.smim.2011.08.010","article-title":"The genetic network controlling plasma cell differentiation","volume":"23","author":"Nutt","year":"2011","journal-title":"Semin Immunol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1038\/s41467-018-04234-4","article-title":"B cell activation and plasma cell differentiation are inhibited by de novo DNA methylation","volume":"9","author":"Barwick","year":"2018","journal-title":"Nat Commun"},{"key":"B138","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/ng.3291","article-title":"Whole-genome fingerprint of the DNA methylome during human B cell differentiation","volume":"47","author":"Kulis","year":"2015","journal-title":"Nat Genet"},{"key":"B139","unstructured":"DNA methylation profiling in human B cells reveals immune regulatory elements and epigenetic plasticity at Alu elements during B-cell activation203041 LaiAY MavD ShahR GrimmSA PhadkeD HatziK 10.1101\/gr.155473.11324013550Genome Res232013"},{"key":"B140","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-lived plasma cells are contained within the CD19\u2013CD38hiCD138+ subset in human bone marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity"},{"key":"B141","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature14192","article-title":"Function and information content of DNA methylation","volume":"517","author":"Sch\u00fcbeler","year":"2015","journal-title":"Nature."},{"key":"B142","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/nature21373","article-title":"Intragenic DNA methylation prevents spurious transcription initiation","volume":"543","author":"Neri","year":"2017","journal-title":"Nature"},{"key":"B143","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"B\u00e9guelin","year":"2013","journal-title":"Cancer Cell"},{"key":"B144","doi-asserted-by":"publisher","first-page":"ji1701470","DOI":"10.4049\/jimmunol.1701470","article-title":"EZH2 represses the B cell transcriptional program and regulates antibody-secreting cell metabolism and antibody production","volume":"200","author":"Guo","year":"2017","journal-title":"J Immunol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1182\/blood-2011-06-357996","article-title":"DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation","volume":"118","author":"Shaknovich","year":"2011","journal-title":"Blood"},{"key":"B146","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cell.2012.08.026","article-title":"Transcriptional amplification in tumor cells with elevated c-Myc","volume":"151","author":"Lin","year":"2012","journal-title":"Cell"},{"key":"B147","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Lov\u00e9n","year":"2013","journal-title":"Cell"},{"key":"B148","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.celrep.2017.09.078","article-title":"UTX\/KDM6A loss enhances the malignant phenotype of multiple myeloma and sensitizes cells to EZH2 inhibition","volume":"21","author":"Ezponda","year":"2017","journal-title":"Cell Rep"},{"key":"B149","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1101\/gr.132738.111","article-title":"A heterozygous IDH1R132H\/WT mutation induces genome-wide alterations in DNA methylation","volume":"22","author":"Duncan","year":"2012","journal-title":"Genome Res"},{"key":"B150","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1093\/nar\/gkw1184","article-title":"MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma","volume":"45","author":"Wang","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"B151","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1126\/science.1170116","article-title":"Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in mammalian DNA by MLL Partner TET1","volume":"324","author":"Tahiliani","year":"2009","journal-title":"Science."},{"key":"B152","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0092-8674(00)81656-6","article-title":"DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development","volume":"99","author":"Okano","year":"1999","journal-title":"Cell"},{"key":"B153","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1182\/blood.V89.7.2500","article-title":"Frequent hypermethylation of p16 and p15 genes in multiple myeloma","volume":"89","author":"Ng","year":"1997","journal-title":"Blood"},{"key":"B154","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1182\/blood-2002-06-1735","article-title":"SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma","volume":"101","author":"Galm","year":"2003","journal-title":"Blood"},{"key":"B155","doi-asserted-by":"publisher","first-page":"4630","DOI":"10.1182\/blood-2003-06-2007","article-title":"SOCS1 and SHP1 hypermethylation in multiple myeloma: Implications for epigenetic activation of the Jak\/STAT pathway","volume":"103","author":"Chim","year":"2004","journal-title":"Blood"},{"key":"B156","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1101\/gr.180240.114","article-title":"Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers","volume":"25","author":"Agirre","year":"2015","journal-title":"Genome Res"},{"key":"B157","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/blood-2010-04-279539","article-title":"Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma","volume":"117","author":"Walker","year":"2011","journal-title":"Blood"},{"key":"B158","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood-2013-03-487884","article-title":"Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma","volume":"122","author":"Kaiser","year":"2013","journal-title":"Blood"},{"key":"B159","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.4049\/jimmunol.1202493","article-title":"Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis","volume":"190","author":"Heuck","year":"2013","journal-title":"J Immunol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1158\/1535-7163.MCT-07-0010","article-title":"5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells","volume":"6","author":"Kiziltepe","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"B161","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.18632\/oncotarget.3207","article-title":"In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma","volume":"6","author":"Maes","year":"2015","journal-title":"Oncotarget"},{"key":"B162","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1182\/blood.V30.1.74.74","article-title":"Melphalan in multiple myeloma","volume":"30","author":"Hoogstraten","year":"1967","journal-title":"Blood"},{"key":"B163","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1001\/jama.1969.03160090040009","article-title":"Treatment for multiple myeloma","volume":"208","author":"Alexanian","year":"1969","journal-title":"JAMA"},{"key":"B164","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood.V67.5.1298.bloodjournal6751298","article-title":"High-dose melphalan with autologous bone marrow transplantation for multiple myeloma","volume":"67","author":"Barlogie","year":"1986","journal-title":"Blood"},{"key":"B165","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"B166","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"B167","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"B168","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/leu.2016.176","article-title":"A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)","volume":"31","author":"H\u00e1jek","year":"2017","journal-title":"Leukemia."},{"key":"B169","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med."},{"key":"B170","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"B171","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/leu.2013.335","article-title":"Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients","volume":"28","author":"Nooka","year":"2014","journal-title":"Leukemia"},{"key":"B172","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"B173","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1182\/blood-2015-05-643320","article-title":"Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma","volume":"126","author":"Shah","year":"2015","journal-title":"Blood"},{"key":"B174","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.1073\/PNAS.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"B175","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"B176","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in north america","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"B177","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"B178","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"key":"B179","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science."},{"key":"B180","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"B181","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science."},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-852798","article-title":"Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice","author":"Fink","year":"2018","journal-title":"Blood"},{"key":"B183","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1182\/blood-2018-05-850727","article-title":"IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos","volume":"132","author":"Fedele","year":"2018","journal-title":"Blood"},{"key":"B184","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"key":"B185","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"B186","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"B187","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science."},{"key":"B188","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"B189","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med."},{"key":"B190","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"key":"B191","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs."},{"key":"B192","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol."},{"key":"B193","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B194","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"key":"B195","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B196","doi-asserted-by":"publisher","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"key":"B197","doi-asserted-by":"publisher","first-page":"eaar7653","DOI":"10.1126\/sciadv.aar7653","article-title":"A tyrosine sulfation\u2013dependent HLA-I modification identifies memory B cells and plasma cells","volume":"4","author":"Chan","year":"2018","journal-title":"Sci Adv"},{"key":"B198","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/leu.2015.208","article-title":"Inhibiting MEK in MAPK pathway-activated myeloma","volume":"30","author":"Heuck","year":"2016","journal-title":"Leukemia"},{"key":"B199","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1016\/j.clml.2014.06.004","article-title":"Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma","volume":"14","author":"Sharman","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B200","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/hon.2353","article-title":"Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation","volume":"35","author":"Mey","year":"2017","journal-title":"Hematol Oncol"},{"key":"B201","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1158\/2159-8290.CD-13-0014","article-title":"Targeting the BRAF V600E mutation in multiple myeloma","volume":"3","author":"Andrulis","year":"2013","journal-title":"Cancer Discov"},{"key":"B202","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/PPO.0000000000000353","article-title":"Targeted management strategies in multiple myeloma","volume":"25","author":"Kumar","year":"2019","journal-title":"Cancer J."},{"key":"B203","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.molcel.2010.01.025","article-title":"The BCL-2 family reunion","volume":"37","author":"Chipuk","year":"2010","journal-title":"Mol Cell"},{"key":"B204","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1038\/emboj.2011.307","article-title":"Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases","volume":"30","author":"Strasser","year":"2011","journal-title":"EMBO J"},{"key":"B205","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.cell.2012.08.038","article-title":"Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML","volume":"151","author":"Vo","year":"2012","journal-title":"Cell"},{"key":"B206","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1126\/science.1206727","article-title":"Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy","volume":"334","author":"Ni Chonghaile","year":"2011","journal-title":"Science"},{"key":"B207","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrc.2015.17","article-title":"Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies","volume":"16","author":"Delbridge","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B208","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.imlet.2013.09.015","article-title":"Reprogramming cell death: BCL2 family inhibition in hematological malignancies","volume":"155","author":"Scarf\u00f2","year":"2013","journal-title":"Immunol Lett"},{"key":"B209","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"B210","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"key":"B211","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1126\/science.1191793","article-title":"Mcl-1 is essential for germinal center formation and B cell memory","volume":"330","author":"Vikstrom","year":"2010","journal-title":"Science."},{"key":"B212","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1182\/blood-2010-11-317438","article-title":"ABT-737 is highly effective against molecular subgroups of multiple myeloma","volume":"118","author":"Bodet","year":"2011","journal-title":"Blood."},{"key":"B213","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2011-01-327197","article-title":"Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL\/Bcl-2 in Mcl-1-expressing myeloma cells","volume":"118","author":"Morales","year":"2011","journal-title":"Blood"},{"key":"B214","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/leu.2013.216","article-title":"The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma","volume":"28","author":"Touzeau","year":"2014","journal-title":"Leukemia"},{"key":"B215","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1182\/blood-2016-03-704908","article-title":"Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1","volume":"128","author":"Gong","year":"2016","journal-title":"Blood"},{"key":"B216","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"B217","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1182\/blood-2018-03-836718","article-title":"BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment","volume":"132","author":"Gomez-Bougie","year":"2018","journal-title":"Blood."},{"key":"B218","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1038\/s41375-018-0374-8","article-title":"Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma","volume":"33","author":"Matulis","year":"2019","journal-title":"Leukemia"},{"key":"B219","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/leu.2015.350","article-title":"Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax","volume":"30","author":"Matulis","year":"2016","journal-title":"Leukemia"},{"key":"B220","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1182\/blood-2016-10-745059","article-title":"Bone marrow microenvironment\u2013derived signals induce Mcl-1 dependence in multiple myeloma","volume":"129","author":"Gupta","year":"2017","journal-title":"Blood"},{"key":"B221","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1002\/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O","article-title":"IL-6 up-regulates Mcl-1 in human myeloma cells through JAK\/STAT rather than Ras\/MAP kinase pathway","volume":"29","author":"Puthier","year":"1999","journal-title":"Eur J Immunol"},{"key":"B222","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1615\/CritRevOncog.2013006145","article-title":"Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism","volume":"18","author":"Mistry","year":"2013","journal-title":"Crit Rev Oncog"},{"key":"B223","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1056\/NEJMoa1508808","article-title":"Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma","volume":"374","author":"Nair","year":"2016","journal-title":"N Engl J Med"},{"key":"B224","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1182\/blood-2005-08-3449","article-title":"Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States","volume":"107","author":"Landgren","year":"2006","journal-title":"Blood"},{"key":"B225","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.cell.2011.07.049","article-title":"Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells","volume":"147","author":"Chiarle","year":"2011","journal-title":"Cell"},{"key":"B226","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/nm.4202","article-title":"Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice","volume":"22","author":"Das","year":"2016","journal-title":"Nat Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01121\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T19:33:57Z","timestamp":1694892837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01121\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,21]]},"references-count":226,"alternative-id":["10.3389\/fimmu.2019.01121"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.01121","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,21]]},"article-number":"1121"}}